版本:
中国

BRIEF-Immunomedics reports preclinical study presented at 2017 AACR annual meeting

April 4 Immunomedics Inc:

* Immunomedics reports immu-132 delivers high levels of sn-38 that overcome chemoresistant tumors with moderate to strong trop-2 expression Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐